Clinical utility of the 70-gene MammaPrint profile in a Japanese population

Japanese Journal of Clinical Oncology

Volumn 40, Issue 6, 2010, Pages 508-512

  Ishitobi, Makoto ^a   Goranova, Teodora E ^a   Komoike, Yoshifumi ^a   Motomura, Kazuyoshi ^a   Koyama, Hiroki ^a   Glas, Annuska M ^b   van Lienen, Ellen ^b   Inaji, Hideo ^a   van't Veer, Laura J ^b   Kato, Kikuya ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b Agendia NV   (Netherlands)

Author keywords

Breast cancer; Gene expression signature; Japanese; Mammaprint; Prognosis

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; FROZEN SECTION; GENE EXPRESSION PROFILING; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; JAPANESE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MICROARRAY ANALYSIS; PROGNOSIS; AXILLA; BREAST TUMOR; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENETICS; JAPAN; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING;

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

AXILLA; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; JAPAN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 77953466956     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp195     Document Type: Article

References (15)

1. Marugame T, Matsuda T, Kamo K, Katanoda K, Ajiki W, Sobue T, et al. Cancer incidence and incidence rates in Japan in 2001 based on the data from 10 population-based cancer registries. Jpn J Clin Oncol 2007;37:884-91.
2. Nemoto T, Tominaga T, Chamberlain A, Iwasa Z, Koyama H, Hama M, et al. Differences in breast cancer between Japan and the United States. J Natl Cancer Inst 1977;58:193-7.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
4. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting Highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-9.
5. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thuerlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
6. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52
7. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
8. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
9. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
10. Buyse M, Loi S, Van't Veer L, Viale G, Delorenzi M, Glas AM, et al. TRANSBIG Consortium. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-9.
11. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 2008;15:2988-93.
12. Nomura Y, Miura S, Koyama H, Enomoto K, Kasumi F, Yamamoto H, et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. A univariate and multivariate analysis of 3089 Japanese patients with breast cancer from the study group for the Japanese breast cancer society on hormone receptors and prognosis in breast cancer. Cancer 1992;69: 153-64.
13. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914-21.
14. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microarray signature into a high throughput diagnostic test. BMC Genom 2006;7:278.
15. Iwamoto E, Fukutomi T, Akashi-Tanaka S. Validation and problems of St. Gallen recommendations of adjuvant therapy for node-negative invasive breast cancer in Japanese patients. Jpn J Clin Oncol 2001;31:259-62.